Qiagen anticipates growth in India, as it sets up subsidiary
Netherlands-based Qiagen (Nasdaq: QGEN), a provider of sample and assay technologies, has established an Indian India subsidiary, Qiagen India Pvt, and the beginning of direct sales in that country, with offices in New Delhi.
Until now, Qiagen products have been sold in India through distributor partnerships. The Dutch company has been active in India since 1995 and has developed numerous initiatives, partnerships and a strong network. The firm expects that this enhanced presence will further contribute to its position in the market, and is a further milestone in Qiagen’s strategy to expand its footprint in emerging, high-growth regions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze